Paraoxonase Activity and Oxidized LDL Levels as Cardiovascular Risk Factors in Patients with Coronary Artery Disease

Ayoglu, Ozgur Bilgin; Ekmekçi, Özlem Balcı; Ekmekçi, Hakan; Ayaoglu, Raif Umut; Belce, Ahmet; Uzun, Hafize

doi:10.5152/imj.2013.20

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that the PON1 rs854560 polymorphism was significantly associated with decreased levels of HDL-C and APOA1 possibly via decreased serum PON1 activity. One possible explanation for this association is that the reduced PON1 enzyme activity might reduce the capacity of PON1-mediated inhibition of LDL oxidation [ 24 , 25 ], which leads to increased levels of plasma ox-LDL (oxidized low-density lipoprotein) [ 26 ] and decreased levels of plasma HDL-C [ 27 ] and APOA1 [ 28 ]. This may also explain our findings.…”

Section: Discussionmentioning

confidence: 99%

Associations of the PON1 rs854560 polymorphism with plasma lipid levels: a meta-analysis

Wang

Irfan

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundPrevious studies have investigated the associations of paraoxonase 1 (PON1) rs854560 polymorphism with plasma lipid levels, but the results are inconclusive. This meta-analysis aimed to clarify the associations of the rs854560 polymorphism with plasma lipid levels.MethodsA comprehensive search of the literature was carried out by using the databases which include Medline, Google Scholar, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang and VIP database up till August 2018. The pooled standardized mean difference (SMD) with 95% confidence interval (CI) was used to assess the differences in lipid levels between the genotypes. Begg’s funnel plots and Egger’s test were used to examine the publication bias.ResultsA total of 41 studies (22,844 subjects) were identified for the associations of rs854560 polymorphism with plasma lipid levels. The M carriers had lower levels of high-density lipoprotein Cholesterol (HDL-C) (SMD = − 0.15, 95% CI = − 0.23--0.07, P < 0.01) and apolipoprotein A-I (APOA1) (SMD = − 0.67, 95% CI = − 0.93--0.41, P < 0.01) than the non-carriers. Subgroup analysis by ethnicity revealed that the effect on HDL level was significant in Caucasians and the subjects of other ethnic origins. No publication bias was detected in this meta-analysis.ConclusionsThe meta-analysis suggests that the PON1 rs854560 polymorphism is associated with a lower HDL-C level in Caucasians and subjects of other ethnic origins.Electronic supplementary materialThe online version of this article (10.1186/s12944-018-0924-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Associations of the PON1 rs854560 polymorphism with plasma lipid levels: a meta-analysis

Wang

Irfan

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention

Singh

Arora

Singh

et al. 2016

American Journal of Therapeutics

View full text Add to dashboard Cite

Vascular inflammation is a key component involved in the process of arthrosclerosis, which in turn increases the risk for cardiovascular injury. In the last 10 years, there have been many trials that looked at omega-3 fatty acids as a way to reduce cardiovascular risk. These trials observed the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the traditional lipid panel and found that both EPA and DHA reduce triglyceride (TG) level and increase high-density lipoprotein cholesterol (HDL-C) levels but also increase the low-density lipoprotein cholesterol (LDL-C) levels. In the 2 more recent trials, the MARINE and ANCHOR, EPA was given as an adjunct therapy to high-risk patients and not only was the traditional lipids measured but also examined the vascular inflammatory biomarkers. The results of these 2 trials not only showed reduction in cardiovascular risk because of reduction in vascular inflammation and reduction in the lipid panel but also showed that one of the MARINE-derived omega-3 fatty acid is superior to the other. Data search for omega-3 fatty acids and cardiovascular risk was performed, and articles were selected for review from 2006 to date. The research studies were all double-blind randomized trials except for one, which was a single-blind and focused on the effects of omega-3 fatty acids on the entire lipid panel. The participants received DHA/EPA and compared with a placebo group on the effect seen in the lipid panel. The first 7 studies looked at the effects of omega-3 fatty acids on TG, LDL-C, and HDL-C; of the 7, 1 directly compared DHA and EPA, 2 focused on EPA, and 4 were directed towards DHA alone. The MARINE and ANCHOR trials were more recent and also looked at the same parameter but also monitored vascular inflammatory biomarkers and how they were affected by omega-3 fatty acids. A second data search was performed for vascular biomarkers and cardiovascular risk, and articles that focused on high-sensitivity C-reactive protein and oxidized low-density lipoprotein were selected for review. Omega-3 fatty acids have shown to decrease TG level in multiple trials, but they have also shown to increase LDL and HDL levels, likely because omega-3 fatty acids promote TG conversion into HDL/LDL. The older data suggested that the benefits of omega-3 fatty acids are nullified by their effects on LDL levels. The data from the MARINE and ANCHOR trials have shown that EPA alone at 4 g per day has shown to decrease TG and total cholesterol without affecting the LDL levels. The earlier data showed that both EPA and DHA decreased TG level and increased levels of HDL-C, but that the DHA alone and direct comparison of DHA/EPA showed that DHA has more undesirable effects on LDL. Furthermore, the MARINE and ANCHOR trials have both shown that not only does EPA improve the lipid panel but also helps to decrease the levels of the vascular inflammatory biomarkers, thus further helping to decrease cardiovascular risk. The use of EPA as an adjunct therapy for high-risk patient has shown to help ...

show abstract

Paraoxonase Activity and Oxidized LDL Levels as Cardiovascular Risk Factors in Patients with Coronary Artery Disease

Cited by 2 publications

References 37 publications

Associations of the PON1 rs854560 polymorphism with plasma lipid levels: a meta-analysis

Associations of the PON1 rs854560 polymorphism with plasma lipid levels: a meta-analysis

Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention

Contact Info

Product

Resources

About